Professur für Molekulare Urologie

Mir-155-5p and mir-203a-3p are prognostic factors in soft tissue sarcoma (2020) Greither T, Koser F, Holzhausen HJ, Güttler A, Würl P, Kappler M, Wach S, Taubert H Journal article Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy (2020) Eckstein M, Strissel P, Strick R, Weyerer V, Wirtz R, Pfannstiel C, Wullweber A, et al. Journal article CCL2 expression in tumor cells and tumor-infiltrating immune cells shows divergent prognostic potential for bladder cancer patients depending on lymph node stage (2020) Eckstein M, Epple E, Jung R, Weigelt K, Lieb V, Sikic D, Stöhr R, et al. Journal article Immune Cell Gene Expression Signature is Associated with Improved Outcome in Muscle-Invasive Urothelial Bladder Cancer Patients Treated with Radical Cystectomy (2020) Eckstein M, Strissel P, Strick R, Weyerer V, Wirtz RM, Pfannstiel C, Wullweber A, et al. Conference contribution RNA sequencing of collecting duct renal cell carcinoma suggests an interaction between miRNA and target genes and a predominance of deregulated solute carrier genes (2020) Wach S, Taubert H, Weigelt K, Hase N, Köhn M, Misiak D, Hüttelmaier S, et al. Journal article Molecular Composition of Genomic TMPRSS2-ERG Rearrangements in Prostate Cancer (2019) Krumbholz M, Agaimy A, Stöhr R, Burger M, Wach S, Taubert H, Wullich B, et al. Journal article Expression of GP88 (Progranulin) Protein Is an Independent Prognostic Factor in Prostate Cancer Patients (2019) Abdulrahman A, Eckstein M, Jung R, Guzman J, Weigelt K, Serrero G, Yue B, et al. Journal article Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial (2019) Jarczyk J, Wirtz R, Roghmann F, Juette H, Kriegmair MC, Worst TS, Sikic D, et al. Conference contribution Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting (2019) Roghmann F, Wirtz R, Jarczyk J, Kriegmair MC, Worst TS, Sikic D, Wach S, et al. Conference contribution Comparative analysis of tumour mutational burden (TMB) prediction methods and its association with determinants of the tumour immune microenvironment of urothelial bladder cancer (UBC) (2019) Eckstein M, Hartmann A, Strissel P, Strick R, Wach S, Taubert H, Wullich B, et al. Conference contribution